No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MIST Milestone Pharmaceuticals
- 1.660
- -0.040-2.35%
Close Apr 24 16:00 ET
88.23MMarket Cap-1194P/E (TTM)
1.710High1.640Low48.68KVolume1.710Open1.700Pre Close81.54KTurnover0.10%Turnover RatioLossP/E (Static)53.15MShares4.49052wk High5.25P/B82.02MFloat Cap1.33052wk Low--Dividend TTM49.41MShs Float27.950Historical High--Div YieldTTM4.12%Amplitude1.330Historical Low1.674Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative
Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company presentation
Milestone Pharmaceuticals To Present Data On Etripamil At The American College Of Cardiology And European Heart Rhythm Association Annual Conferences
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present d
Express News | Milestone Pharmaceuticals Disclosed Resubmission Of New Drug Application For Etripamil For Treatment In Paroxysmal Supraventricular Tachycardia
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innova
Comments
Despite significant insider shares, Milestone Pharmaceuticals noted fairly low insider ownership. The absence of recent insider transactions is raising concerns. It's more encouraging if insiders bought more shares in the company.
ColumnsWall Street Today | S&P 500 Inches Closer to Record High
RECAP
S&P 500 Approaches All-Time High
US stocks rose, with the $S&P 500 Index(.SPX.US$ approaching its all-time, high as optimism over potential interest rate cuts next year continued to fuel positive sentiment on the last trading week of the year.
The S&P 500 closed 0.42% higher at 4,774.75 on the first day of the holiday-shortened trading week. The $Nasdaq Composite Index(.IXIC.US$ gained 0.5% to 15,074.57, while the $Dow Jones Industrial Average(.DJI.US$ added 0.4...
S&P 500 Approaches All-Time High
US stocks rose, with the $S&P 500 Index(.SPX.US$ approaching its all-time, high as optimism over potential interest rate cuts next year continued to fuel positive sentiment on the last trading week of the year.
The S&P 500 closed 0.42% higher at 4,774.75 on the first day of the holiday-shortened trading week. The $Nasdaq Composite Index(.IXIC.US$ gained 0.5% to 15,074.57, while the $Dow Jones Industrial Average(.DJI.US$ added 0.4...
26
5
FDA ANSWER! Yuck! Hehehe
$Milestone Pharmaceuticals(MIST.US$ Milestone Pharmaceuticals Received An FDA Refusal To File Letter For The New Drug Application For Self-administered Etripamil Nasal Spray For Paroxysmal Supraventricular Tachycardia
1
Watching
$Milestone Pharmaceuticals(MIST.US$ Milestone Pharmaceuticals Reports Submission Of New Drug Application To FDA For Etripamil
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg